Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model

S. V. Kocheril, David Grignon, C. Y. Wang, R. L. Maughan, E. J. Montecillo, B. Talati, S. Tekyi-Mensah, J. E. Pontes, G. G. Hillman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We have tested an immunotherapy approach for the treatment of metastatic prostate carcinoma using a bone tumor model. Human PC-3 prostate carcinoma tumor cells were heterotransplanted into the femur cavity of athymic Balb/c nude mice. Tumor cells replaced marrow cells in the bone cavity, invaded adjacent bone and muscle tissues, and formed a palpable tumor at the hip joint. PC-3/IF cell lines, generated from bone tumors by serial in vivo passages, grew with faster kinetics in the femur and metastasized to inguinal lymph nodes. Established tumors were treated with systemic interleukin-2 (1L-2) injections. IL-2 significantly inhibited the formation of palpable tumors and prolonged mouse survival at nontoxic low doses. Histologically IL-2 caused vascular damage and infiltration of polymorphonuclear cells and lymphocytes in the tumor as well as necrotic areas with apoptotic cells. These findings suggest destruction of tumor cells by systemic 1L-2 therapy and IL-2 responsiveness of prostate carcinoma bone tumors.

Original languageEnglish (US)
Pages (from-to)408-416
Number of pages9
JournalCancer Detection and Prevention
Volume23
Issue number5
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Heterografts
Interleukin-2
Prostate
Carcinoma
Bone and Bones
Neoplasms
Therapeutics
Femur
Groin
Hip Joint
Nude Mice
Bone Marrow Cells
Immunotherapy
Blood Vessels
Lymph Nodes
Lymphocytes
Cell Line
Muscles
Injections

Keywords

  • Bone tumors
  • Immunotherapy
  • Prostate carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model. / Kocheril, S. V.; Grignon, David; Wang, C. Y.; Maughan, R. L.; Montecillo, E. J.; Talati, B.; Tekyi-Mensah, S.; Pontes, J. E.; Hillman, G. G.

In: Cancer Detection and Prevention, Vol. 23, No. 5, 1999, p. 408-416.

Research output: Contribution to journalArticle

Kocheril, SV, Grignon, D, Wang, CY, Maughan, RL, Montecillo, EJ, Talati, B, Tekyi-Mensah, S, Pontes, JE & Hillman, GG 1999, 'Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model', Cancer Detection and Prevention, vol. 23, no. 5, pp. 408-416. https://doi.org/10.1046/j.1525-1500.1999.99039.x
Kocheril, S. V. ; Grignon, David ; Wang, C. Y. ; Maughan, R. L. ; Montecillo, E. J. ; Talati, B. ; Tekyi-Mensah, S. ; Pontes, J. E. ; Hillman, G. G. / Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model. In: Cancer Detection and Prevention. 1999 ; Vol. 23, No. 5. pp. 408-416.
@article{a02d23171b014ad89e8cba3c2ba14bc1,
title = "Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model",
abstract = "We have tested an immunotherapy approach for the treatment of metastatic prostate carcinoma using a bone tumor model. Human PC-3 prostate carcinoma tumor cells were heterotransplanted into the femur cavity of athymic Balb/c nude mice. Tumor cells replaced marrow cells in the bone cavity, invaded adjacent bone and muscle tissues, and formed a palpable tumor at the hip joint. PC-3/IF cell lines, generated from bone tumors by serial in vivo passages, grew with faster kinetics in the femur and metastasized to inguinal lymph nodes. Established tumors were treated with systemic interleukin-2 (1L-2) injections. IL-2 significantly inhibited the formation of palpable tumors and prolonged mouse survival at nontoxic low doses. Histologically IL-2 caused vascular damage and infiltration of polymorphonuclear cells and lymphocytes in the tumor as well as necrotic areas with apoptotic cells. These findings suggest destruction of tumor cells by systemic 1L-2 therapy and IL-2 responsiveness of prostate carcinoma bone tumors.",
keywords = "Bone tumors, Immunotherapy, Prostate carcinoma",
author = "Kocheril, {S. V.} and David Grignon and Wang, {C. Y.} and Maughan, {R. L.} and Montecillo, {E. J.} and B. Talati and S. Tekyi-Mensah and Pontes, {J. E.} and Hillman, {G. G.}",
year = "1999",
doi = "10.1046/j.1525-1500.1999.99039.x",
language = "English (US)",
volume = "23",
pages = "408--416",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model

AU - Kocheril, S. V.

AU - Grignon, David

AU - Wang, C. Y.

AU - Maughan, R. L.

AU - Montecillo, E. J.

AU - Talati, B.

AU - Tekyi-Mensah, S.

AU - Pontes, J. E.

AU - Hillman, G. G.

PY - 1999

Y1 - 1999

N2 - We have tested an immunotherapy approach for the treatment of metastatic prostate carcinoma using a bone tumor model. Human PC-3 prostate carcinoma tumor cells were heterotransplanted into the femur cavity of athymic Balb/c nude mice. Tumor cells replaced marrow cells in the bone cavity, invaded adjacent bone and muscle tissues, and formed a palpable tumor at the hip joint. PC-3/IF cell lines, generated from bone tumors by serial in vivo passages, grew with faster kinetics in the femur and metastasized to inguinal lymph nodes. Established tumors were treated with systemic interleukin-2 (1L-2) injections. IL-2 significantly inhibited the formation of palpable tumors and prolonged mouse survival at nontoxic low doses. Histologically IL-2 caused vascular damage and infiltration of polymorphonuclear cells and lymphocytes in the tumor as well as necrotic areas with apoptotic cells. These findings suggest destruction of tumor cells by systemic 1L-2 therapy and IL-2 responsiveness of prostate carcinoma bone tumors.

AB - We have tested an immunotherapy approach for the treatment of metastatic prostate carcinoma using a bone tumor model. Human PC-3 prostate carcinoma tumor cells were heterotransplanted into the femur cavity of athymic Balb/c nude mice. Tumor cells replaced marrow cells in the bone cavity, invaded adjacent bone and muscle tissues, and formed a palpable tumor at the hip joint. PC-3/IF cell lines, generated from bone tumors by serial in vivo passages, grew with faster kinetics in the femur and metastasized to inguinal lymph nodes. Established tumors were treated with systemic interleukin-2 (1L-2) injections. IL-2 significantly inhibited the formation of palpable tumors and prolonged mouse survival at nontoxic low doses. Histologically IL-2 caused vascular damage and infiltration of polymorphonuclear cells and lymphocytes in the tumor as well as necrotic areas with apoptotic cells. These findings suggest destruction of tumor cells by systemic 1L-2 therapy and IL-2 responsiveness of prostate carcinoma bone tumors.

KW - Bone tumors

KW - Immunotherapy

KW - Prostate carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0032873536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032873536&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1500.1999.99039.x

DO - 10.1046/j.1525-1500.1999.99039.x

M3 - Article

C2 - 10468893

AN - SCOPUS:0032873536

VL - 23

SP - 408

EP - 416

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

IS - 5

ER -